A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Functional Constipation Clinical Trial

Official title:

A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Less Than 2 Years of Age With Functional Constipation (FC).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05760313
• Other study ID #: M21-862
• Secondary ID: 2022-501947-34-0
• Status: Recruiting
• Phase: Phase 2
• Start date: April 27, 2023
• Est. completion date: September 30, 2025

Study information

• Verified date: May 2024
• Source: AbbVie
• Contact: ABBVIE CALL CENTER
• Phone: 844-663-3742
• Email: abbvieclinicaltrials[@]abbvie.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and fluid intake, and immobility. Currently, there are no pharmacological therapies approved for the treatment of FC. This study will assess adverse events and change in disease activity with linaclotide therapy in participants with FC. Linaclotide is an approved drug being developed for the treatment of FC in pediatric patients who meet modified Rome IV criteria for childhood FC. In Part 1 of this study, participants are placed in 3 groups, which occur consecutively. Each group receives a different dosage of linaclotide. In Part 2 of the study, participants will be randomly assigned to receive either linaclotide or placebo. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 30 pediatric participants 6 months to less than 2 years of age with FC will be enrolled in the study at about 25 sites worldwide. Participants will receive oral solution of linaclotide prepared from capsule by parent/guardian once daily for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 30, 2025
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 23 Months

Eligibility

Inclusion Criteria:

• Individuals must be 6 months to less than 1 year and 11 months old, at the time the legally authorized representative (LAR)/parent/guardian signs the informed consent in alignment with local requirements.
• The LAR/parent/guardian who will be completing the electronic diary (eDiary) is able to read and understand the assessments in the eDiary device and must undergo training.
• Participant meets modified Rome IV criteria for functional constipation (FC): for at least 1 month before Screening (Visit 1), the participant must meet 2 or more of the

following:

• 2 or fewer defecations per week (with each defecation occurring in the absence of any laxative, suppository, or enema use during the preceding 24 hours)
• History of excessive volitional stool retention
• History of painful or hard bowel movements (BMs)
• History of large-diameter stools
• Presence of a large fecal mass in the rectum
• LAR/Parent/Guardian is willing to discontinue any laxatives used before the Preintervention Visit in favor of the protocol-permitted rescue medicine.

Exclusion Criteria:

• Participant has conditions that could interfere with drug absorption, including, but not limited to, short bowel syndrome.
• History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the individual's participation in this study or would make the participant an unsuitable candidate to receive study drug.
• Participant has history of:
• Celiac disease, or positive serological test for celiac disease or the condition is suspected but has not been ruled out by endoscopic biopsy
• Cystic fibrosis
• Hypothyroidism that is untreated or treated with thyroid hormone at a dose that has not been stable for at least 3 months prior to Screening (Visit 1)
• Down's syndrome or any other chromosomal disorder
• Active anal fissure (investigator has confirmed an active anal fissure and participant reports known anal fissure symptoms [i.e., streaks of blood on the stool or on diaper or toilet paper and pain/crying with bowel movement within 2 weeks prior to Screening]). (Note: Anal fissures that have resolved at least 2 weeks prior to screening would not be exclusionary). However, if in the investigator's opinion, an anal fissure(s) may be the primary cause of participant's modified Rome IV FC criteria, the subject would not be eligible to participate in the study.
• Anatomic malformations (e.g., imperforate anus, anal stenosis, anterior displaced anus)
• Intestinal nerve or muscle disorders (e.g., Hirschprung disease, visceral myopathies, visceral neuropathies)
• Neuropathic conditions (e.g., spinal cord abnormalities, neurofibromatosis, tethered cord, spinal cord trauma)
• Lead toxicity, hypercalcemia
• Neurodevelopmental disabilities of the LAR/Parent/Guardian/Caregiver who will be completing the eDiary (early-onset, chronic disorders that share the essential feature of a predominant disturbance in the acquisition of cognitive, motor, language, or social skills, which has a significant and continuing impact on the developmental progress of an individual) producing a cognitive delay that precludes comprehension and completion of the daily eDiary or other study-related questionnaires.
• Inflammatory bowel disease
• Lactose intolerance that is associated with symptoms which could confound the assessments in this study
• History of cancer. (Note: Participants with a history of cancer are allowed provided that the malignancy has been in a complete remission before enrollment/randomization (Visit 3). A complete remission is defined as the disappearance of all signs of cancer in response to treatment)

Related Conditions & MeSH terms

• Constipation
• Functional Constipation

Intervention

Drug:
• Linaclotide
Capsule; oral
• Placebo
Capsule; oral

Locations

Country	Name	City	State
Bulgaria	UMHAT Sveti Georgi /ID# 250808	Plovdiv
Bulgaria	UMHAT Kanev /ID# 248931	Ruse
Bulgaria	Acibadem City Clinic Tokuda University Hospital EAD /ID# 251232	Sofia
Bulgaria	Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 251229	Sofiya
Bulgaria	Nova Clinic /ID# 249023	Varna
Croatia	Klinicki bolnicki centar Osijek /ID# 252795	Osijek
Croatia	Klinicki bolnicki centar Sestre milosrdnice /ID# 252798	Zagreb	Grad Zagreb
Croatia	Klinicki bolnicki centar Zagreb /ID# 252796	Zagreb	Grad Zagreb
Croatia	Klinika za djecje bolesti Zagreb /ID# 252792	Zagreb	Grad Zagreb
Germany	Kinderarztpraxis Dr. Froehlich /ID# 252050	Forchheim
Germany	Universitaetsklinikum Muenster /ID# 251965	Muenster	Nordrhein-Westfalen
Germany	HELIOS Klinikum Wuppertal /ID# 249022	Wuppertal
Hungary	Debreceni Egyetem-Klinikai Kozpont /ID# 250793	Debrecen	Hajdu-Bihar
United Kingdom	Russells Hall Hospital /ID# 252660	Dudley
United Kingdom	Barts Health NHS Trust /ID# 252298	London	London, City Of
United Kingdom	Great Ormond Street Hospital for Children /ID# 253333	London	London, City Of
United Kingdom	Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 252299	Norwich	Norfolk
United States	Advanced Research Center /ID# 248763	Anaheim	California
United States	Coastal Pediatric Research - West Ashley B /ID# 248693	Charleston	South Carolina
United States	Kindred Medical Institute - Corona /ID# 251535	Corona	California
United States	Prohealth Research Center /ID# 248696	Doral	Florida
United States	Michigan Center of Medical Research /ID# 253536	Farmington Hills	Michigan
United States	Velocity Clinical Research- Hastings Nebraska /ID# 260932	Hastings	Nebraska
United States	HealthStar Research of Hot Springs PLLC /ID# 251553	Hot Springs	Arkansas
United States	Houston Clinical Research Associates /ID# 261571	Houston	Texas
United States	South Miami Medical & Research Group Inc. /ID# 248765	Miami	Florida
United States	Virgo Carter Pediatrics /ID# 251555	Silver Spring	Maryland
United States	Coastal Pediatric Research - Summerville /ID# 253534	Summerville	South Carolina
United States	ClinPoint Trials /ID# 251534	Waxahachie	Texas

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie	Ironwood Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Bulgaria,  Croatia,  Germany,  Hungary,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in overall Spontaneous Bowel Movement (SBM) frequency rate (SBMs/week) during the Study Intervention Period	An SBM is defined as a BM that occurs in the absence of laxative, enema, or suppository use on the calendar day of the BM or the calendar day before the BM. The caregiver/parent/guardian/legally authorized representative (LAR) will complete the electronic diary (eDiary), providing data for the SBM frequency rate up to the last dose date equivalent to the 4-week SBM frequency rate.	Baseline to Week 4
Primary	Change from baseline in stool consistency (Bristol Stool Form Scale) during the Study Intervention Period	The caregiver/parent/guardian/legally authorized representative (LAR) will rate and record in an eDiary the consistency of the stool for each BM using the Bristol Stool Form 7-point scale in which 1=Separate hard lumps, like nuts (hard to pass); 2=Sausage-shaped, but lumpy; 3=Like a sausage but with cracks on its surface; 4=Like a sausage or snake, smooth and soft; 5=Soft blobs with clear cut edges (easy to pass); 6=Fluffy pieces with ragged edges, a mushy stool; and 7=Watery, no solid pieces, entirely liquid.	Baseline to Week 4
Primary	Change from baseline in straining during the Study Intervention Period	The caregiver/parent/guardian/LAR will rate and record in an eDiary the amount of straining they observe when the child passes the BM.	Baseline to Week 4
Primary	Number of Participants with Adverse Events (AEs)	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.	Up to Week 5

External Links

•   Related Info